No Data
SymbolStock Name
PriceChg% ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D % Chg10D % Chg20D % Chg60D % Chg120D % Chg250D % Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
Watchlist
US OptionsDetailed Quotes
ANAB250117P45000
- 0.00
- 0.000.00%
15min DelayClose Dec 23 09:30 ET
0.00High0.00Low
0.00Open0.00Pre Close0 Volume0 Open Interest45.00Strike Price0.00Turnover0.00%IV-222.12%PremiumJan 17, 2025Expiry Date31.03Intrinsic Value100Multiplier24DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type--Delta--Gamma--Leverage Ratio--Theta--Rho--Eff Leverage--Vega
Intraday
- 5D
- Daily
No Data
News
Shareholders in AnaptysBio (NASDAQ:ANAB) Have Lost 60%, as Stock Drops 13% This Past Week
Truist Financial Maintains AnaptysBio(ANAB.US) With Hold Rating, Maintains Target Price $20
J.P. Morgan Maintains AnaptysBio(ANAB.US) With Buy Rating, Cuts Target Price to $36
JP Morgan Maintains Overweight on AnaptysBio, Lowers Price Target to $36
Truist Financial Maintains AnaptysBio(ANAB.US) With Hold Rating, Announces Target Price $20
Stifel Maintains AnaptysBio(ANAB.US) With Buy Rating, Cuts Target Price to $41